Ironwood Pharmaceuticals Future Growth

Future criteria checks 4/6

Ironwood Pharmaceuticals is forecast to grow earnings and revenue by 54.9% and 10% per annum respectively while EPS is expected to grow by 50.1% per annum.

Key information

54.9%

Earnings growth rate

50.1%

EPS growth rate

Biotechs earnings growth	27.6%
Revenue growth rate	10.0%
Future return on equity	n/a
Analyst coverage	Good
Last updated	18 Dec 2024

Recent future growth updates

Recent updates

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 21

Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S

Oct 24

Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Aug 16

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough

Jun 27

Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC

Jun 20

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Feb 16

Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential

Jan 31

Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Dec 19

Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

Jul 25

An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Apr 18

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Mar 28

Ironwood Pharmaceuticals: Rinse, Wash And Repeat

Oct 05

These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Sep 28

Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh

Jul 29

Earnings and Revenue Growth Forecasts

NasdaqGS:IRWD - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	416	84	N/A	283	4
12/31/2025	348	37	120	141	6
12/31/2024	353	22	109	125	6
9/30/2024	378	-2	124	124	N/A
6/30/2024	401	9	146	147	N/A
3/31/2024	414	-1,052	148	148	N/A
12/31/2023	443	-1,002	183	183	N/A
9/30/2023	432	-952	227	227	N/A
6/30/2023	427	-917	263	263	N/A
3/31/2023	417	182	290	290	N/A
12/31/2022	411	175	274	274	N/A
9/30/2022	421	168	259	259	N/A
6/30/2022	416	173	265	265	N/A
3/31/2022	422	527	252	252	N/A
12/31/2021	414	528	262	262	N/A
9/30/2021	413	530	249	249	N/A
6/30/2021	413	509	227	227	N/A
3/31/2021	398	143	199	199	N/A
12/31/2020	390	106	167	169	N/A
9/30/2020	399	111	140	145	N/A
6/30/2020	427	97	118	126	N/A
3/31/2020	440	84	88	97	N/A
12/31/2019	428	59	4	11	N/A
9/30/2019	433	19	-12	-8	N/A
6/30/2019	367	-153	-69	-69	N/A
3/31/2019	346	-173	-81	-82	N/A
12/31/2018	347	-194	-71	-71	N/A
9/30/2018	310	-190	-90	-89	N/A
6/30/2018	331	-71	N/A	-94	N/A
3/31/2018	315	-108	N/A	-104	N/A
12/31/2017	298	-55	N/A	-101	N/A
9/30/2017	292	-143	N/A	-110	N/A
6/30/2017	271	-143	N/A	-80	N/A
3/31/2017	260	-121	N/A	-53	N/A
12/31/2016	274	-82	N/A	-26	N/A
9/30/2016	240	-82	N/A	-26	N/A
6/30/2016	213	-96	N/A	-52	N/A
3/31/2016	187	-123	N/A	-71	N/A
12/31/2015	150	-143	N/A	-107	N/A
9/30/2015	134	-166	N/A	-110	N/A
6/30/2015	112	-161	N/A	-123	N/A
3/31/2015	91	-173	N/A	-133	N/A
12/31/2014	76	-190	N/A	-156	N/A
9/30/2014	43	-204	N/A	-175	N/A
6/30/2014	31	-224	N/A	-194	N/A
3/31/2014	34	-229	N/A	-238	N/A
12/31/2013	23	-273	N/A	-273	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IRWD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: IRWD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IRWD is expected to become profitable in the next 3 years.

Revenue vs Market: IRWD's revenue (10% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: IRWD's revenue (10% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IRWD's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 05:21
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ironwood Pharmaceuticals, Inc. is covered by 37 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Raghuram Selvaraju	Aegis Capital Corporation
Geoffrey Meacham	Barclays
Patrick Trucchio	Berenberg

Ironwood Pharmaceuticals Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for Full Year 2024

Price target increased by 11% to US$12.67

Consensus EPS estimates fall by 50%

Price target decreased by 13% to US$14.17

Ironwood Pharmaceuticals, Inc. Revises Earnings Guidance for Its Fiscal Year 2024

Price target decreased by 9.3% to US$16.33

Recent updates

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Third quarter 2024 earnings: EPS misses analyst expectations

Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for Full Year 2024

Price target increased by 11% to US$12.67

Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S

Consensus EPS estimates fall by 50%

Investor sentiment deteriorates as stock falls 20%

Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 13% to US$14.17

New minor risk - Share price stability

Ironwood Pharmaceuticals, Inc. Revises Earnings Guidance for Its Fiscal Year 2024

Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) dropped from Russell 2000 Growth-Defensive Index

Insufficient new directors

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough

Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC

Independent Chairman of the Board notifies of intention to sell stock

Independent Director recently sold US$518k worth of stock

Independent Director notifies of intention to sell stock

CEO & Director recently sold US$436k worth of stock

CEO & Director notifies of intention to sell stock

Price target decreased by 9.3% to US$16.33

Ironwood Pharmaceuticals, Inc. Revised Earnings Guidance for Its Fiscal Year 2024

First quarter 2024 earnings released: US$0.03 loss per share (vs US$0.30 profit in 1Q 2023)

Ironwood Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

New minor risk - Shareholder dilution

Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)

Price target decreased by 10% to US$18.50

New minor risk - Share price stability

New minor risk - Insider selling

Full year 2023 earnings: EPS misses analyst expectations

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2024

CEO & Director notifies of intention to sell stock

Price target increased by 11% to US$19.83

Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential

Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for the Fiscal Year 2023 and Provides Earnings Guidance for the Fiscal Year 2024

Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Consensus EPS estimates fall by 42%

Ironwood Pharmaceuticals, Inc. provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Ironwood Pharmaceuticals, Inc. Provids Earnings Guidance for the Year 2023

Ironwood Pharmaceuticals, Inc. Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting

Ironwood Pharmaceuticals, Inc. Presents Positive Final Data from Stars Nutrition, A Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity

Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

Price target increased by 15% to US$16.50

Senior VP recently bought US$300k worth of stock

Ironwood Pharmaceuticals, Inc. Revises Financial Guidance for the Year 2023

New major risk - Negative shareholders equity

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old

CEO & Director notifies of intention to sell stock

CEO & Director recently sold US$364k worth of stock

Price target increased by 12% to US$14.33

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Ironwood Pharmaceuticals, Inc. Presents Results from Phase III Clinical Trial in Pediatric Patients

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

CEO & Director notifies of intention to sell stock

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Senior VP & COO recently sold US$388k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations